MX339899B - Compuestos de triazolopiridina como inhibidores de pim cinasa. - Google Patents

Compuestos de triazolopiridina como inhibidores de pim cinasa.

Info

Publication number
MX339899B
MX339899B MX2013009820A MX2013009820A MX339899B MX 339899 B MX339899 B MX 339899B MX 2013009820 A MX2013009820 A MX 2013009820A MX 2013009820 A MX2013009820 A MX 2013009820A MX 339899 B MX339899 B MX 339899B
Authority
MX
Mexico
Prior art keywords
pim
compounds
triazolopiridine
cinasa
inhibitors
Prior art date
Application number
MX2013009820A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009820A (es
Inventor
Wang Bin
F Blake James
Kirk Delisle Robert
A De Meese Lisa
m graham James
Le Huerou Yvan
Lyon Michael
e robinson John
M Wallace Eli
Xu Rui
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2013009820A publication Critical patent/MX2013009820A/es
Publication of MX339899B publication Critical patent/MX339899B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013009820A 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de pim cinasa. MX339899B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446902P 2011-02-25 2011-02-25
PCT/US2012/026572 WO2012154274A1 (en) 2011-02-25 2012-02-24 Triazolopyridine compounds as pim kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013009820A MX2013009820A (es) 2014-09-01
MX339899B true MX339899B (es) 2016-06-16

Family

ID=46000320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009820A MX339899B (es) 2011-02-25 2012-02-24 Compuestos de triazolopiridina como inhibidores de pim cinasa.

Country Status (32)

Country Link
US (1) US8889704B2 (cg-RX-API-DMAC7.html)
EP (1) EP2678329B1 (cg-RX-API-DMAC7.html)
JP (2) JP6039585B2 (cg-RX-API-DMAC7.html)
KR (1) KR101940338B1 (cg-RX-API-DMAC7.html)
CN (1) CN103492377B (cg-RX-API-DMAC7.html)
AR (1) AR085489A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012254082B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013021675A2 (cg-RX-API-DMAC7.html)
CA (1) CA2828269C (cg-RX-API-DMAC7.html)
CL (1) CL2013002446A1 (cg-RX-API-DMAC7.html)
CO (1) CO6771441A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130460A (cg-RX-API-DMAC7.html)
CY (1) CY1117197T1 (cg-RX-API-DMAC7.html)
DK (1) DK2678329T3 (cg-RX-API-DMAC7.html)
ES (1) ES2563152T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160134T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027675T2 (cg-RX-API-DMAC7.html)
IL (1) IL228108A (cg-RX-API-DMAC7.html)
ME (1) ME02365B (cg-RX-API-DMAC7.html)
MX (1) MX339899B (cg-RX-API-DMAC7.html)
PH (1) PH12013501754A1 (cg-RX-API-DMAC7.html)
PL (1) PL2678329T3 (cg-RX-API-DMAC7.html)
RS (1) RS54586B1 (cg-RX-API-DMAC7.html)
RU (1) RU2598846C2 (cg-RX-API-DMAC7.html)
SG (1) SG192944A1 (cg-RX-API-DMAC7.html)
SI (1) SI2678329T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600052B (cg-RX-API-DMAC7.html)
TW (1) TWI529170B (cg-RX-API-DMAC7.html)
UA (1) UA111075C2 (cg-RX-API-DMAC7.html)
UY (1) UY33924A (cg-RX-API-DMAC7.html)
WO (1) WO2012154274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306997B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
KR20150013137A (ko) * 2012-04-25 2015-02-04 에프. 호프만-라 로슈 아게 (3,4-다이클로로-페닐)-((s)-3-프로필-피롤리딘-3-일)-메탄온 하이드로클로라이드 및 제조 방법
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
JP7160688B2 (ja) * 2016-05-24 2022-10-25 ジェネンテック, インコーポレイテッド Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
US20220363667A1 (en) 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种(3r,4s)-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种(3s,4r)-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ, インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN113195469B (zh) * 2019-02-19 2024-05-24 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
AU2020250468A1 (en) 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513975A (ja) 1999-11-12 2003-04-15 ニューロゲン コーポレイション 二環式および三環式のヘテロ芳香族化合物
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
HRP20030719A2 (en) 2001-03-09 2005-04-30 Pfizer Products Inc. Triazolopyridines as anri-inflammatory agents
US7227006B2 (en) 2002-01-19 2007-06-05 Sanofi-Aventis Deutschland Gmbh PIM-3 kinase as a target for type 2 diabetes mellitus
RU2005122484A (ru) 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
EP1581526B1 (en) 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
EP1781655A2 (en) 2004-08-18 2007-05-09 Pharmacia & Upjohn Company LLC Triazolopyridine compounds useful for the treatment of inflammation
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
AU2006302174B2 (en) 2005-10-06 2013-06-20 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
WO2007145921A1 (en) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
AU2007316417B2 (en) 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AR065495A1 (es) * 2007-03-02 2009-06-10 Schering Corp Metodos para usar derivados de bencimidazol para tratar o prevenir dolor, diabetes, complicacion diabetica composiciones.
JP2010522765A (ja) * 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物
CN101679423A (zh) * 2007-04-03 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
TWI496779B (zh) * 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US20110184013A1 (en) * 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
JP2012521428A (ja) * 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のp2x3受容体アンタゴニスト

Also Published As

Publication number Publication date
US20140005213A1 (en) 2014-01-02
KR20140021577A (ko) 2014-02-20
UY33924A (es) 2013-09-30
MX2013009820A (es) 2014-09-01
UA111075C2 (uk) 2016-03-25
CL2013002446A1 (es) 2014-04-11
AU2012254082B2 (en) 2016-12-08
EP2678329A1 (en) 2014-01-01
CO6771441A2 (es) 2013-10-15
PL2678329T3 (pl) 2016-06-30
BR112013021675A2 (pt) 2016-11-01
ME02365B (me) 2016-06-20
AR085489A1 (es) 2013-10-09
NZ615300A (en) 2014-12-24
CR20130460A (es) 2013-10-16
TW201245193A (en) 2012-11-16
US8889704B2 (en) 2014-11-18
HK1190714A1 (zh) 2014-07-11
PH12013501754A1 (en) 2013-10-14
JP6039585B2 (ja) 2016-12-07
CA2828269A1 (en) 2012-11-15
SI2678329T1 (sl) 2016-05-31
HRP20160134T1 (hr) 2016-04-08
CY1117197T1 (el) 2017-04-05
JP2014509322A (ja) 2014-04-17
EP2678329B1 (en) 2015-11-18
CN103492377B (zh) 2016-04-20
IL228108A0 (en) 2013-09-30
RU2013143292A (ru) 2015-04-10
AU2012254082A1 (en) 2013-09-26
CA2828269C (en) 2019-01-15
ES2563152T3 (es) 2016-03-11
RU2598846C2 (ru) 2016-09-27
CN103492377A (zh) 2014-01-01
HUE027675T2 (en) 2016-11-28
RS54586B1 (sr) 2016-08-31
SMT201600052B (it) 2016-04-29
SG192944A1 (en) 2013-09-30
IL228108A (en) 2017-07-31
TWI529170B (zh) 2016-04-11
WO2012154274A1 (en) 2012-11-15
ZA201306997B (en) 2015-05-27
JP2016106118A (ja) 2016-06-16
DK2678329T3 (da) 2016-02-22
KR101940338B1 (ko) 2019-01-18

Similar Documents

Publication Publication Date Title
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
EA201201648A1 (ru) Стимуляторы sgc
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA201590748A1 (ru) Противовирусные соединения против rsv
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201071320A1 (ru) Активаторы глюкокиназы
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
SV2011003855A (es) Heteroarilos sustituidos
IN2014CN03597A (cg-RX-API-DMAC7.html)
IN2015DN01151A (cg-RX-API-DMAC7.html)
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EA201591024A1 (ru) Димерные соединения
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CR20130610A (es) Método de tratamiento de la fiebre dengue

Legal Events

Date Code Title Description
FG Grant or registration